Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; collaboration with AdvanCell to advance novel targeted alpha therapies for the treatment of cancer; and Chugai Pharmaceutical Co., Ltd. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Eli Lilly and Company

Bristol Gate Capital Partners Inc., managed by Richard Hamm, recently executed a significant transaction involving Eli Lilly And Company (($LLY)). ...

Bristol Gate’s Richard Hamm Trims Eli Lilly Stake

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Eli Lilly & Co (LLY) and Ascendis Pharma (ASND). E...

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Ascendis Pharma (ASND)

Novo Nordisk ($NVO) CEO Mike Doustdar is defending the European drug maker’s lawsuit against U.S. rival Eli Lilly ($LLY) over what it alleges is fa...

Novo Nordisk CEO Defends Lawsuit Against Eli Lilly (LLY)

Canaccord Genuity analyst Brian McNamara maintained a Buy rating on Holley yesterday and set a price target of $7.00. The company’s shares closed y...

Canaccord Genuity Remains a Buy on Holley (HLLY)

Gamco Investors, Inc. ET AL, managed by Mario Gabelli, recently executed a significant transaction involving Eli Lilly And Company (($LLY)). The he...

Gamco Investors’ Mario Gabelli Ups Stake in Eli Lilly

Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Eli Lilly & Co on August 11 and set a price target of $1,376.00. The compa...

Truist Financial Sticks to Their Buy Rating for Eli Lilly & Co (LLY)

Vanguard ETFs are popular with investors for their broad diversification at lower costs and exposure to major parts of the market. For investors st...

3 Vanguard ETFs That Could Turn $1,000 Into Long-Term Wealth

The company continues to see strong sales of its weight-loss drugs. 


Five-Star Analyst Raises Price Target on Eli Lilly Stock (LLY) After Blowout Earnings

U.S. stocks finished a strong week with another rally on Friday after a surprisingly weak jobs report pushed investors to rethink the path for inte...

The Week That Was, The Week Ahead: Macro and Markets, August 9

Companies in the Consumer Cyclical sector have received a lot of coverage today as analysts weigh in on Holley (HLLY), Booking Holdings (BKNG) and ...

Analysts Offer Insights on Consumer Cyclical Companies: Holley (HLLY), Booking Holdings (BKNG) and Portillo’s (PTLO)

Shopify ($SHOP), Booking ($BKNG), and Eli Lilly ($LLY) were among the most active and best-performing stocks on Wednesday. More importantly, all th...

3 Most Active ‘Strong Buy’ Stocks with Market-Topping Gains — August 6, 2026

The pharma giant hasn’t split its shares since 1997. 


Rumors Swirl That Eli Lilly (LLY) Will Split Its Stock After Blockbuster Earnings

The company beat Wall Street forecasts across the board. 


Novo Nordisk Stock (NVO) Recovers as Earnings Surprise to the Upside

Suncoast Equity Management, managed by Donald R. Jowdy, recently executed a significant transaction involving Eli Lilly And Company (($LLY)). The h...

Suncoast Equity Management trims Eli Lilly position

Planning for retirement doesn’t have to mean picking dozens of investments. A few low-cost Vanguard ETFs can provide broad market exposure, steady ...

3 Best Vanguard ETFs for Stress-Free Retirement Investing

Wall Street investment bank Goldman Sachs ($GS) is bucking consensus, forecasting weak sales of Eli Lilly’s ($LLY) new weight-loss pill when the co...

Goldman Sachs Forecasts Weak Obesity Pill Sales from Eli Lilly (LLY)

Telsey Advisory analyst Joe Feldman maintained a Buy rating on Holley today and set a price target of $5.00. Feldman covers the Consumer Cyclical s...

Holley (HLLY) Receives a Buy from Telsey Advisory

Companies in the Financial sector have received a lot of coverage today as analysts weigh in on Independent Bank (IBCP), Ally Financial (ALLY) and ...

Analysts’ Opinions Are Mixed on These Financial Stocks: Independent Bank (IBCP), Ally Financial (ALLY) and Robinhood (HOOD)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Eli Lilly & Co (LLY) and Kyverna Therapeutics, Inc. ...

Analysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), Kyverna Therapeutics, Inc. (KYTX)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Aurora Cannabis (ACB), Eli Lilly & Co (LLY) and Tyra Bioscience (...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Aurora Cannabis (ACB), Eli Lilly & Co (LLY) and Tyra Bioscience (TYRA)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Eli Lilly & Co (LLY) and Atricure (ATRC) with bullis...

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Atricure (ATRC)

The two companies dominate the market for obesity medications. 


Novo Nordisk Pursues Injunction to Block Eli Lilly’s (LLY) Advertisements

The new medication helps people who also have diabetes and cardiovascular disease. 


Eli Lilly (LLY) Targets 2027 for Approval of Its Next-Generation Obesity Drug

In a report released today, from Ord Minnett maintained a Hold rating on CSL, with a price target of A$123.30. In addition to Ord Minnett, CSL also...

Ord Minnett Reaffirms Their Hold Rating on CSL (CMXHF)

SoFi’s ($SOFI) fintech premium will be on trial when the company reports its Q2 results on July 29 before the opening bell. Although the core lendi...

SoFi Stock’s Fintech Premium Is on Trial in Q2

There’s a lot to be optimistic about in the Financial sector as 2 analysts just weighed in on Capital One Financial (COF) and Ally Financial (ALLY)...

Analysts Are Bullish on Top Financial Stocks: Capital One Financial (COF), Ally Financial (ALLY)

Analysts have been eager to weigh in on the Financial sector with new ratings on Ally Financial (ALLY), Wintrust Financial (WTFC) and Hancock Whitn...

Analysts’ Opinions Are Mixed on These Financial Stocks: Ally Financial (ALLY), Wintrust Financial (WTFC) and Hancock Whitney (HWC)

In a report released today, Emily Field from Barclays maintained a Buy rating on Eli Lilly & Co, with a price target of $1,400.00. According to Tip...

Barclays Sticks to Its Buy Rating for Eli Lilly & Co (LLY)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Tyra Bioscience (TYRA), Eli Lilly & Co (LLY) and Per...

Analysts Are Bullish on These Healthcare Stocks: Tyra Bioscience (TYRA), Eli Lilly & Co (LLY)

RBC Capital analyst Craig Wong-Pan maintained a Hold rating on CSL on July 16 and set a price target of A$108.00. The company’s shares closed last ...

RBC Capital Sticks to Their Hold Rating for CSL (CMXHF)

In a report released yesterday, Harry Gillis from Berenberg Bank maintained a Hold rating on Eli Lilly & Co, with a price target of $1,135.00. Acco...

Eli Lilly & Co (LLY) Gets a Hold from Berenberg Bank

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. Eli Lilly And Company (LLY) is running a new long‑term safety stu...

Lilly Expands ALS Pipeline With Long‑Term Safety Study for LY4256984

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. Eli Lilly and Company is running a Phase 1 trial called “A Phase ...

Lilly Quietly Expands Its Obesity Pipeline With New Early-Stage LY4174794 Trial

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. The long term follow up study of AAVAnc80-antiVEGF gene therapy a...

Lilly-Backed Gene Therapy Study Tracks Long Term Safety in Vestibular Schwannoma

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. The Phase 1 study titled “A Phase 1, Investigator- and Participan...

Eli Lilly Expands Obesity Pipeline With New Phase 1 Eloralintide Trial

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. Eli Lilly and Company (LLY) is running a Phase 1 study called “A ...

Lilly’s Tersolisib Food-Effect Study Moves Forward, Adding Depth to Its Early-Stage Pipeline

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. The Phase 1 study A Phase 1 Study to Investigate the Pharmacokine...

Eli Lilly’s New Phase 1 Trial for LY4268989 Signals Fresh Pipeline Momentum

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. Eli Lilly and Company (LLY) has completed a Phase 2 study titled ...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	LLY	$1,180.16	-2.25%	2.27M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	LLY	$1,180.16	-2.2%	2.27M
3
4
5
6

LLY

Get Eli Lilly and Company Data in Excel

Get Eli Lilly and Company Data in Excel